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Summary 
The injection of naked plasmid DNA directly into the muscle cells of mice has been shown to 
induce potent humoral and cellular immune responses. The generation of a cytotoxic T  lym- 
phocyte (CTL) response after plasmid DNA injection may involve the presentation of the ex- 
pressed antigen in the context of the injected myocytes' endogenous major histocompatibility 
(MHC)-encoded class I molecules or may use the MHC molecules of bone marrow-derived 
antigen presenting cells  (APC) which are capable of providing co-stimulation as well.  To re- 
solve which  cell type provides the specific restricting element for this method of vaccination 
we  generated  parent--+F1  bone  marrow  chimeras in  which  H-2  bxa recipient  mice  received 
bone marrow that expressed only H-2  b or H-2  d MHC molecules.  These mice were injected 
intramuscularly with naked plasmid DNA that encoded the nucleoprotein from the A/PR/8/ 
34 influenza strain, which as a single antigen has epitopes for both H-2D  b and H-2K  a. The re- 
sulting CTL responses were restricted to the MHC haplotype of the bone marrow alone and 
not to the second haplotype expressed by the recipient's myocytes. The role of somatic tissues 
that express protein from injected plasmids may be to serve as a reservoir for that antigen which 
is then transferred to the APC. Consequently, our data show that the mechanism of priming in 
this novel method for vaccination uses the MHC from bone marrow-derived APC, which are 
efficient at providing all of the necessary signals for priming the T  cell. 
D 
irect  injection  of naked  plasmid DNA  either  intra- 
muscularly or intradermally induces strong, long-lived 
immune responses to the antigen encoded by the gene vac- 
cine. While the intradermal route of administration appears 
to be the most efficient, there is evidence that either route 
leads to production of antibody and the activation of both 
major histocompatibility  complex  (MHC)  class I-restricted, 
antigen-specific cytotoxic T lymphocytes (CTL) and MHC 
class  II-restricted  CD4  T  cells  secreting  Thl-type  cyto- 
kines (1-9).  Plasmid DNA immunization has potential ad- 
vantages compared to traditional protein vaccination due to 
the strong CTL and Thl  responses induced, the prolonged 
antigen expression, and the resistance of the antigen source 
to  antibody  mediated  clearance.  As  a  consequence,  gene 
vaccination has potential applications in the fields of infec- 
tious diseases,  allergy and cancer. 
The question of the mechanism by which DNA vaccines 
activate the immune system has been raised by a number of 
investigators  (6,  10).  The majority of CD4 T  cells  recog- 
nize  peptides  derived  from  exogenous  proteins  endocy- 
tosed by antigen-presenting cells  (APC),  degraded to pep- 
tide  fragments  and  loaded  onto  MHC  class  II molecules 
(11).  In contrast, CD8 T  cells generally recognize peptides 
derived from endogenous proteins presented in the context 
of MHC  class I molecules.  Peptides derived from proteo- 
some  processing  of intracellular  proteins  are  transported 
into  the  lumen  of the  endoplasmic  reticulum  by  mem- 
brane-associated transporters of antigenic peptides (TAP-1 
and TAP-2). These peptides then bind nascent MHC class 
I  complexes  (12-15).  This  endogenous  route  of peptide 
loading onto MHC  class I molecules would be most effi- 
ciently used after gene vaccination if the protein were ex- 
pressed by the antigen-presenting cells. 
Theoretically,  this  does  not  pose  a  great  problem  in 
terms of intradermal gene vaccination. Within  the  dermis 
of the skin, there are a variety of "professional" APC such 
as Langerhans  cells,  dendritic  cells  and tissue macrophages 
which  could be transfected by the injected plasmid DNA 
(12).  Indeed, intradermal gene vaccination has been shown 
to induce expression of the gene product in cells with mac- 
rophage like morphology as well as keratinocytes and der- 
mal fibroblasts (1). 
Within  muscle  tissue,  professional APC  are  sparse,  al- 
though they may be recruited to muscle by the local irrita- 
tion that follows injection (10,  13,  14).  Consequently, it is 
unlikely  that  these  APC  would  be  transfected by the  in- 
jected DNA.  Muscle cells  are transfected by the gene and 
produce  a  protein  product  (15);  however,  numerous  ex- 
perimental systems have shown that presentation of antigen 
by non-professional APC which lack appropriate co-stimu- 
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T  cells (16-19).  This poses the following question: which 
cell type presents gene encoded antigen to prime the im- 
mune system after intramuscular gene vaccination? 
Although not answering this question directly, a number 
of experiments have provided a theoretical basis by which 
such priming could occur.  Non-professional APC such as 
transfected fibroblasts are able to induce an antigen-specific 
MHC class I-restricted response if they are physically relo- 
cated to secondary lymphoid tissue (20).  This implies that 
antigen presentation and co-stimulation do not need to be 
provided by the same cell but must be in the same local en- 
vironrflent. Thus it is possible that CTL could receive a first 
signal from peptide/MHC class  I  complexes expressed by 
the  muscle  tissue  and  a  second  signal from  hemopoietic 
ceils recruited by a local inflammatory response to the site 
of injection. 
In addition, it  has  been  shown  that  under certain  cir- 
cumstances  exogenous  antigens  can  be  presented  in  the 
context of MHC  class  I  (21-30).  Consequently, presenta- 
tion may occur by protein transfer from transfected muscle 
to  a  professional APC.  This  potential mechanism is  sup- 
ported by the original cross-priming experiments in which 
bystander cells were shown to present MHC class I-restricted 
minor histocompatibility antigens in vivo (31)  and by more 
recent experiments in which a test antigen expressed by tu- 
mors of one haplotype can cross-prime CTL restricted to 
another MHC haplotype when transferred to  F1  recipient 
mice (32). 
The primary aim of the  experiments reported here was 
to  determine whether somatic  cells at  the  site  of plasmid 
DNA injection can prime a specific CTL response by pre- 
senting antigen in the  context of their endogenous MHC 
complexes or whether presentation is restricted to  profes- 
sional APC ofhemopoietic origin. 
Materials  and Methods 
Parental-gFl  Bone Marrow Chimeras.  Female BALB/c,  C57B1/6, 
and CB6  F1  mice (C57B1/6  ￿  BALB/c) were purchased  from 
Jackson  Laboratories  (Bar Harbor, Maine). CB6 mice, aged  10- 
12 wk, were used as bone marrow recipients.  To minimize the 
risk  of bacterial  infection before  reconstitution, recipient mice 
were fed autoclaved food and housed in micro-isolator cages with 
autoclaved  bedding. Antibiotics were  given (sulfamethoxazole/ 
trimethoprim) in their drinking water for 5 d pre-irradiation, and 
for 3 wk post-irradiation. This regimen was supplemented with 
intranmscular injection of antibiotics (gentamicin)  during the first 
week post irradiation.  Recipient female CB6 F1 mice were given 
1,200 rads and then injected intravenously with 5  ￿  10  (' T  de- 
pleted bone marrow cells from 5-wk-old donor female BALB/c, 
C57B1/6, or CB6 F1 mice in a total volume of 1(10 ILl serum-free 
RPMI  1640 (BioWhittaker, Walkersville,  MD).  Chimerism was 
confirmed at time of death  by cytofluorographic  analysis of har- 
vested splenocytes. 
T  Cell Depletion of Bone Marrow.  Bone marrow was expressed 
from the tibia and femurs  of 5-wk-old donor nfice using sterile 
serum-free tLPMI  1640,  a  3-ml syringe  and 22-gauge  needle. 
Bone marrow preparations  were depleted  of T cells by treatment 
with a cocktail ofanti-Thy-1 (YTS 154), anti-CD4 (RL172),  and 
anti-CD8 (3.155)  antibodies at 4~  followed  by batch selected 
guinea pig complement (PelFreez Biologicals,  Rogers, AK) and 
10 ~g/ml DNAase I (Sigma Chem. Co., St. Louis, MO) at 37~ 
Cells were then washed  and viable cells counted. The efficiency 
of depletion was  then tested  by antibody staining of cells and 
analysis on the cytofluorograph. 
Cytofluorographic Analysis.  T depleted bone marrow was stained 
using antibodies against CD4 and CD8 coupled to phycoerythrin 
(Caltag,  San  Francisco,  CA).  Staining antibodies were  selected 
which bound to alternative  epitopes  of CD4 and CD8 to the de- 
pleting antibodies to avoid false readings due to competition. Sple- 
nocytes from bone marrow chimeric mice were analyzed at the 
time of death.  Cells were stained  with either anti-Thy-l-FITC 
(Caltag)  to  determine number of T  cells, anti-B220-PE (Phar- 
Mingen, La Jolla,  CA)  to determine B cell levels and antibodies 
against  H-2b-PE and  H-2d-FITC (PharMingen) alone and  to- 
gether to  determine whether all the  leukocytes  were  of donor 
type  or whether residual  recipient (H-2  d and H-2  b)  leukocytes 
still remained. Cells were then analyzed oll the FACScan  ~ flow 
cytometer (Becton-Dickinson, San Jose,  CA)  using the Lysys II 
analysis  programs.  All  mice  used  in  these  experiments  were 
shown to contain less than 4% of residual recipients leukocytes. 
Preparation ofPlasmid DNA.  The  nCMV-int and  nCMV-NP 
vectors  have  been described  previously (1). DNA was prepared 
using Qiagen maxiprep kits (Qiagen,  Chatsworth, CA), with the 
modification of adding  one-tenth volume  10%  Triton  X-114 
(Sigma) to the clarified bacterial  lysate before applying it to the 
colunm in the kit.  Before  injection the residual endotoxin level 
was  quantified using a  limulus extract  clot assay (Associates of 
Cape Cod, Woods Hole, MA). Plasmid DNA with a level of<5 
ng endotoxin/mg DNA was resuspended  in sterile isotonic saline 
solution before injection. 
lmmunizatiou of Mia'.  Unmanipulated adult nfice (>12-wk-old, 
BALB/c, C57B1/6, and CB6 F1 mice) were injected intramuscu- 
larly in the rear quadriceps with 100 b~g of either nCMV-NP en- 
coding the influenza virus nucleoprotein (four mice per group) or 
nCMV-int as control (three mice per group)  in a total volume of 
50 p~l saline using a 25-gauge needle. Injections were given twice, 
separated by a two-week interval.  Four weeks after the final in- 
jection, mice were killed and spleens removed tbr in vitro restim- 
ulation of CTL.  Bone  marrow  chimeric  mice  (four  mice  per 
group)  were  injected as  above,  beginning six  and eight weeks 
post bone marrow transplant.  Six weeks after the final DNA im- 
nmnization, mice were killed by cervical dislocation  and spleens 
removed for in vitro restimulation of CTL. 
Assay,fi~r CTL.  Mice were killed by cervical dislocation, their 
spleens removed and teased apart in R,  PMI media supplemented 
with  2%  fetal  bovine serum  (FBS). In  24-well  plates  (Costar, 
Cambridge, MA) 7  ￿  lff  ~  responder splenocytes were incubated 
with 6 X 106 stimulator splenocytes  (derived from C57B1/6 mice 
or BALB/c nfice) in the presence  of 50 IU/ml recombinant IL2. 
The culture media was RPMI 1640 supplemented with 10% heat- 
inactivated FBS, 2  mM glutamine, 50  mM  2-mercaptoethanol, 
and 1% penicillin and streptomycin. The stinmlator cells were ir- 
radiated  (2,000 rads) syngeneic splenocytes  pulsed with 4 I~g/mt 
synthetic peptide (Molecular Research Laboratories, Durham, NC). 
Synthetic NP peptides  used  were TYQRTRALV (restricted  to 
H-2K  d) and ASNENMETM (restricted to H-2D  b) (33). After 5 d 
the  restinmlated cells were  harvested  and separated  from  dead 
cells on a Lympholyte M  (Accurate  Chemicals,  Westbury, NY) 
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bated in 200-bd volumes with restimulated T  cells at graded  el- 
lector to target ratios for 4 h. Assay medium used was phenol red- 
free RPMI1640 supplemented with 2% BSA,  2 mM glutamine 
and 1% penicillin, and streptomycin. The target  cells used were 
either EL4, an H-2  b thymoma cell line, or P185,  an H-2  a masto- 
cytoma cell line. 50  txl/well of the supernatant was then trans- 
ferred to a 96-well plates and lysis was assessed by measuring lac- 
tate  dehydrogenase  release  using  the  Cytotox  96  assay kit 
(Promega  Corp., Madison, WI). Controls were included on each 
plate for spontaneous LDH release from target and effector cells. 
Percent lysis was calculated  according to the manufacturer's in- 
structions by a formula that approximates  to: 
(test release - spontaneous  release)  x 100. 
(maximum  release - spontaneous  release) 
Results  and  Discussion 
Intramuscular Injection of Plasmid DNA  Encoding the Influ- 
enza  Virus Nudeoprotein  (NP) is a Highly Effective Method of 
Inducing NP-specific CTL  Intramuscular gene  immuniza- 
tion ofunmanipulated  C57B1/6, BALB/c or F1  (C57B1/6 ￿ 
BALB/c)  mice with plasmid DNA encoding the gene for 
influenza virus nucleoprotein (NP)  of A/PR/8/34  influ- 
enza strain was highly effective at inducing strong NP-spe- 
cific CTL (Fig. 1). Groups of four mice of each strain were 
immunized intramuscularly with either 100 ~g of nCMV- 
NP or control vector, nCMV-int, at weeks 0  and 2. Mice 
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Figure  1.  Intramuscular  injection ofplasmid DNA encoding the influ- 
enza vires nucleoprotein (NP) induces NP-specific, H-2-restricted CTL 
in C57B1/6, BALB/c, and CB6 F1 strains. Mice were immunized intra- 
muscularly  with 100 txg ofnCMV-NP (or nCMV-int as control) at week 
0 and week 2. Mice were killed at week 6 and restimulated  in vitro with 
irradiated splenocytes  pulsed with the appropriate H-2-restricted NP pep- 
tide. After 5 d in culture, the specificity  of the resulting CTL was deter- 
mined by measuring  their ability to lyse either EL4 cells pulsed with the 
H-2Di'-restricted NP peptide ASNENMETM (A) or P815 cells pulsed 
with the H-2Kd-restricted peptide TYQP.TRALV (B). The maximum 
nonspecific  lysis  for EL4 cells pulsed with the H-2b-binding  control pep- 
tide (ovalbumin  257-264:SIINFEKL)  was 0.2% for CB6 mice and 2% for 
C57B1/6 mice (A) and the maximal  nonspecific  lysis  for P815 cells pulsed 
with the H-2d-binding  peptide ([3-galactosidase 876-884: TPHPAP.IGL) 
was 5% for CB6 and 3% for BALB/c mice (B). Data are expressed as per- 
centage specific lysis. Background  lysis  of unpulsed  EL4 and P815 cells has 
been subtracted from lysis  values of peptide pulsed cells. Values given are 
means and standard errors of groups of four mice. O,  C57B1/6 injected 
with nCMVNP; ~,  C57B1/6 injected with nCMVint; tin-, CB6 in- 
jected with nCMVNP; -[[[]-, CB6 injected with nCMVint; -lk, BALB/c 
injected with nCMVNP; -/X-,  BALB/c injected  with nCMVint. 
were killed at week 6 and after in vitro restimulation their 
splenocytes were assayed for their ability to lyse H-2  u target 
cells  pulsed  with  the  H-2DU-restricted peptide  from  NP 
residues  366-374  or  H-2  d  target  cells  pulsed  with  the 
H-2Ka-restricted  peptide  from  NP  residues  147-155.  A 
single plasmid encoding NP was able to induce the genera- 
tion of specific H-2b-restricted CTL in both C57B1/6  and 
F1 mice and H-2d-restricted CTL in both BALB/c and F1 
mice. The F1  mice were capable of processing the NP an- 
tigen such that CTL were generated to both the H-2  b- and 
H-2d-restricted epitopes in the same animal (Fig.  1, A  and 
/3). The primary signal for this priming may have been ei- 
ther from the MHC/peptide complexes on the  myocytes 
or from bone marrow-derived APC. 
Intramuscular Plasmid  DNA  Injection of Parent-->F1 Bone 
Marrow  Chimeras  Yields CTL Restricted to the Parental (Bone 
Marrow-derived) Haplotype.  Muscle cells injected with plas- 
mid DNA can produce large amounts of the gene encoded 
protein (15).  The  efficacy of intramuscular plasmid DNA 
injection  for  inducing  antigen-specific  CTL  combined 
with the relative paucity of professional APC at the site of 
injection  and  an  apparent  tendency  of  non-professional 
APC  to  induce tolerance rather  than  immunity, leads  to 
the question of whether muscle cells themselves can act as 
antigen-presenting cells  or  whether  protein  (or  DNA)  is 
transferred to hemopoietic cells which then stimulate anti- 
gen responsive T  cells. 
To determine the relative roles of bone marrow-derived 
APC  and  muscle  cells  in  the  induction of the  CTL  re- 
sponse to  intramuscular immunization with DNA encod- 
ing influenza virus nucleoprotein we generated parent--+F1 
chimeras.  F1  hybrid mice were  given lethal irradiation to 
obliterate  their  immune  system,  and  then  reconstituted 
with T-depleted bone marrow of either parental haplotype 
(or T-depleted bone marrow from CB6  F1  mice as  con- 
trol).  This  generated chimeric  mice  whose  muscle  ceils 
were  of both  H-2  b and H-2  a haplotypes,  and whose  im- 
mune system had  the  potential to  recognize  antigens re- 
stricted by either haplotype due to  the presence of an F1 
thymus (34), but whose bone marrow-derived APC could 
only present antigen in the context of one parental haplo- 
type. 
Mice were immunized intramuscularly as described above 
and  six  weeks  after  the  final injection were  killed,  their 
spleens removed and splenocytes restimulated in vitro be- 
fore  assay  for  CTL.  At the  time of death,  chimerism was 
confirmed by cytofluorographic analysis of the splenocytes 
which  showed  that  all mice had  <4%  residual recipient's 
leukocytes.  As  shown  in  Fig.  2,  immunization of  par- 
ent--+F1  chimeras  with  nCMV-NP  induced  NP-specific 
CTL that were restricted only to  the haplotype found on 
the parental bone marrow-derived APC and not the alter- 
native haplotype also expressed by somatic cells. This find- 
ing was true regardless of whether the bone marrow donor 
was of H-2  b (A) or H-2  a (C) haplotype. Mice reconstituted 
with  CB6  bone marrow  produced  NP-specific  CTL  re- 
stricted to  either H-2  b or H-2  a (B). Control mice injected 
1557  Corr et al.  Brief Definitive Report H-2  b Bone Marrow 
oo t  .... 
.'~_~  401 ~ 
H-2  bid Bone Marrow  H-2 d Bone Marrow 
i  i  i  i 
0  10  20  30  40  50  0  10  20  30  40  50  0  10  20  30  40  50 
E:T Ratio 
Figure 2.  Intramuscular  plasmid DNA injection of parent-+F1 bone 
marrow chimeras yields CTL restricted to the parental (bone marrow- 
derived) haplotype. CB6 F1 mice were lethally irradiated and reconsti- 
tuted with T depleted bone marrow from C57B1/6 (A), CB6 F1 (B) and 
BALB/c (C) mice. At weeks six and eight after reconstitution  mice were 
immunized  intramuscularly  with 100 p,g of nCMV-NP (closed  symbols) or 
nCMV-int as control (open  symbols). Mice were killed at week 14. Half of 
the splenocytes from each mouse were restimulated in vitro with H-2  {~ 
and the other half  with H-2  b irradiated splenocytes  pulsed with the appro- 
priate peptides. After 5 d culture, the H-2 restriction  of the resulting  CTL 
was determined by measuring  their ability to lyse either EL4 cells pulsed 
with the H-2Db-restricted NP peptide ASNENMETM (circle) or P815 
cells pulsed with the H-2KJ-restricted peptide TYQRTRALV  (square). 
The maximal  nonspecific  lysis for EL4 cells pulsed with the H-2b-binding 
control peptide (SIINFEKL) was 6%1 (A), 2% (B), and 3% (C), respec- 
tively. For  P815 cells pulsed with  the  H-2a-binding peptide (TPH- 
PARIGL) the maximal  nonspecific  lysis  was 4% (A), 2% (/3), and 2% (C), 
respectively. Data are expressed as percentage-specific lysis. Background 
lysis of unpulsed  EL4 and P815 cells has been subtracted from lysis values 
of peptide pulsed cells. Values given  are means  and standard errors of groups 
of four mice. 0-, nCMVNP/ restimulated  with H-2b; KD-, nCMVint/ 
restimulated with H-2b; l-,  nCMVNP/  restimulated with H-2d; q[]-, 
nCMVint/restinmlated with H-2  ~. 
with nCMV-int failed to produce significant levels of CTL. 
These data indicate that muscle cells at the site of plasmid 
DNA injection do  not  themselves present gene  encoded 
antigen to the immune system. Instead, presentation occurs 
at the surface of a professional bone marrow-derived APC. 
Such APC may be directly transfected by plasmid DNA at 
the site of injection, resulting in endogenous expression of 
NP.  Loading  of NP  derived  cytoplasmic  peptides  onto 
MHC class I molecules can then occur through the endog- 
enous pathway involving  proteosomes and TAP complexes 
(35-38).  However,  the  paucity of professional bone mar- 
row-derived APe  at  the  site  of injection, favors  the  hy- 
pothesis that gene transfected muscle cells produce NP pro- 
tein which is then transferred to conventional APC. 
It has now been shown by a number of groups that ex- 
ogenous protein molecules can prime MHC class I-restricted 
CTL responses (22, 23) when administered as either partic- 
ulate or denatured protein. Alternatively, peptide fragments 
or denatured proteins can be transferred intercellularly by 
heat shock protein chaperones  (39).  Presentation involves 
endocytosis/phagocytosis of the  protein by  either macro- 
phages or dendritic cells (22, 23, 25). Loading of MHC class I 
molecules  may  occur  externally by  peptides  regurgitated 
from phagosomes of the same or neighboring cells  (26, 40) 
or  internally, either  through  leakage  of digested  proteins 
into the cytosol due to phagocytic overload (25),  or through 
a phagosome  to  cytoplasm shuttle  (24)  which  then feeds 
peptides into the  conventional TAP-dependent pathway 
for MHC class I loading. Recent experiments analyzing  pre- 
sentation  of  tumor-associated  antigens  by  bone  marrow- 
derived APe support this latter mechanism by demonstrat- 
ing an absolute requirement for functional TAP expression 
by the bone marrow-derived APC (41). 
In  summary,  intramuscular injection of plasmid  DNA 
encoding the  influenza virus  nucleoprotein results  in the 
induction of NP-specific CTL restricted to the MHC class I 
molecules expressed by bone marrow-derived APC. 
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